KRS Capital Management’s Puma Biotechnology PBYI Stock Holding History

KRS Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-58	Closed	–	–	277
2021 Q4	$0	Buy	+58	New	+$252	﹤0.01%	393

Other funds holding PBYI

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

KRS Capital Management's PBYI Position: Q1 2022 in Review

KRS Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2022, closing a stake of 58 shares.

KRS Capital Management first reported a position in PBYI in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 104 funds tracked by Wall St. Rank hold PBYI as of Q1 2022.

KRS Capital Management reported no remaining Puma Biotechnology position as of Q1 2022 after selling out during the quarter.
KRS Capital Management sold 58 Puma Biotechnology shares in Q1 2022.
KRS Capital Management first reported a position in Puma Biotechnology in Q4 2021 and held it in 1 quarter.
KRS Capital Management's Puma Biotechnology position peaked at $0 in Q4 2021.
104 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.